MicroPort CardioFlow Medtech Corporation has announced the formal release of one-year follow-up results from the early feasibility study of AltaValveTM, a transcatheter mitral valve replacement (TMVR) device developed by its associated company, 4C Medical Technologies, Inc. The study, conducted across multiple centers in Europe, the United States, and Japan, enrolled 30 patients with symptomatic severe mitral regurgitation who were considered high surgical risk. The results have already been presented. The company has also recently completed a USD175 million Series D financing round to support global clinical trials and commercialization efforts for AltaValveTM. MicroPort CardioFlow Medtech Corporation holds exclusive commercial rights for AltaValveTM in Mainland China, Hong Kong, Macau, and Taiwan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Cardioflow Medtech Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251230-11971804), on December 30, 2025, and is solely responsible for the information contained therein.